Journal
CANCER TREATMENT REVIEWS
Volume 53, Issue -, Pages 98-110Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.ctrv.2016.12.009
Keywords
Angiogenesis; Breast cancer; Bevacizumab; VEGF; Sorafenib; Sunitinib; Ramucirumab
Categories
Funding
- Fonds Cancer (FOCA) from Belgium
Ask authors/readers for more resources
Angiogenesis is one of the hallmarks of cancer and a crucial requisite in the development of tumors. Interrupting this process by blocking the vascular endothelial growth factor (VEGF) with the monoclonal antibody bevacizumab has been considered a possible breakthrough in the treatment of various types of cancer, especially for advanced disease. However in breast cancer, studies have shown ambivalent results causing debate about the value of this drug. In this article, we review the evidence for anti-angiogenic treatment options for breast cancer, as well as discuss the possible factors limiting the effectiveness of anti-angiogenic agents and offer a recommendation regarding the future research on these therapies for the treatment of breast cancer. (C) 2016 Elsevier Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available